Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.5.1.18 (
glutathione S-transferase
)
22,582
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Our attempts to find a physiologically relevant means for inducing leukotriene synthesis in rat peritoneal mononuclear cells have thus far been unsuccessful in addition to the IgE-anti-IgE challenge which we previously reported, we have now tried human C3a and C5a as well as crude and semipurified fractions of the prostaglandin-generating factor of anaphylaxis. In each case, it was possible to show that these substances activated the cells even though no leukotrienes were formed. A cell-free system in which LTC +
LTD
formation can be studied was developed as a modification of published methods. Arachidonic acid and LTA4 served as precursors in this system in the presence of added glutathione. Calcium was required for LTC and
LTD
synthesis from arachidonic acid but was not required for the
glutathione S-transferase
terminal step in the synthesis. Using inhibitor profiles, substrate specificity for chromogenic substrates, and inactivation by selective antibodies, we tried to identify the subtype of the
glutathione S-transferase
in RBL cells. Although antibody to type E of the enzyme was most effective in neutralizing the enzyme activity, neither the substrate specificity nor the inhibition profiles agreed with the conclusion that the E-type enzyme was the major form in these cells. The effect of known inhibitors of
glutathione S-transferase
on the conversion of arachidonate to LTC and
LTD
was examined. Bilirubin, an inhibitor which binds to the enzyme and is not a substrate, was much more active in inhibiting LTC +
LTD
formation than were steroid sulfates, which were markedly less active in inhibiting this reaction. The inhibitory activities of the other compounds were similar on all substrates tested.
...
PMID:Formation of leukotrienes C and D and Pharmacologic modulation of their synthesis. 612 95
The proinflammatory mediator leukotriene D(4) (
LTD
(4)) binds to the seven-transmembrane receptor CYSLT(1). Although this leukotriene plays an important biological role, its intracellular signaling pathways are only partly known. In previous experiments, we found that
LTD
(4) induced tyrosine phosphorylation and translocation of phospholipase (PLC)-gamma1 to a plasma membrane fraction in a human epithelial cell line (Int 407). In the present study, we further examined these signaling events and found that
LTD
(4) induced a rapid interaction between Gbetagamma subunits and PLC-gamma1; results obtained with
GST
fusion proteins of PLC-gamma1 suggest that this interaction is mediated via the pleckstrin homology domain of PLC-gamma1. Moreover,
LTD
(4) induced an increased association of c-Src with PLC-gamma1, and the selective Src family tyrosine kinase inhibitor PP1 blocked both
LTD
(4)-induced tyrosine phosphorylation of PLC-gamma1 and the association of PLC-gamma1 with Gbetagamma subunits. The relevance of these observations in intracellular calcium signaling was investigated by microinjecting cells with anti-Gbeta, anti-PLC-gamma1, or anti-c-Src antibodies and by pretreatment with PP1.
LTD
(4)-induced calcium mobilization was blocked by each of the indicated antibodies (but not isotype-matched control antibodies) and by PP1. Our data suggest that Gbetagamma subunits can, directly or indirectly, serve as membrane-bound partners for PLC-gamma1 and c-Src and that each of these proteins is essential for
LTD
(4)-induced downstream PLC-gamma1 signaling.
...
PMID:Leukotriene D(4) triggers an association between gbetagamma subunits and phospholipase C-gamma1 in intestinal epithelial cells. 1073 40
Leukotrienes (LTs) are biologically active compounds derived from arachidonic acid which have important pathophysiological roles in asthma and inflammation. The cysteinyl leukotriene LTC(4) and its metabolites
LTD
(4) and LTE(4) stimulate bronchoconstriction, airway mucous formation and generalized edema formation. LTC(4) is formed by addition of glutathione to LTA(4), catalyzed by the integral membrane protein, LTC(4) synthase (LTCS). We now report the use of bioluminescence resonance energy transfer (BRET) to demonstrate that LTCS forms homo-oligomers in living cells. Fusion proteins of LTCS and Renilla luciferase (Rluc) and a variant of green fluorescent protein (GFP), respectively, were prepared. High BRET signals were recorded in transiently transfected human embryonic kidney (HEK 293) cells co-expressing Rluc/LTCS and GFP/LTCS. Homo-oligomer formation in living cells was verified by co-transfection of a plasmid expressing non-chimeric LTCS. This resulted in dose-dependent attenuation of the BRET signal. Additional evidence for oligomer formation was obtained in cell-free assays using
glutathione S-transferase
(
GST
) pull-down assay. To map interaction domains for oligomerization, GFP/LTCS fusion proteins were prepared with truncated variants of LTCS. The results obtained identified a C-terminal domain (amino acids 114-150) sufficient for oligomerization of LTCS. Another, centrally located, interaction domain appeared to exist between amino acids 57-88. The functional significance of LTCS homo-oligomer formation is currently being investigated.
...
PMID:Leukotriene C4 synthase homo-oligomers detected in living cells by bioluminescence resonance energy transfer. 1288 Aug 68
Montelukast, a selective reversible cysteinyl leukotriene D(4)-receptor (
LTD
(4) receptor) antagonist, is used in the treatment of asthma. We have investigated alterations in the glutathione (GSH) and activity levels of antioxidative enzymes [superoxide dismutase (SOD), catalase (CAT),
glutathione S-transferase
(
GST
), and glutathione reductase (GR)] and myeloperoxidase (MPO), as markers of the ulceration process following oral administration of montelukast, lansoprazole, famotidine, and ranitidine, respectively, in rats with indomethacin-induced ulcers. In the present study, we found that 1) montelukast, lansoprazole, famotidine, and ranitidine all reduced the development of indomethacin-induced gastric damage, with this reduction occurring at a greater magnitude for montelukast, famotidine, and lansoprazole than for ranitidine; 2) montelukast and ranitidine both alleviated increases in the activity levels of CAT and
GST
enzymes resulting from gastric injury; 3) montelukast and ranitidine both ameliorated depressions in the GSH and activity levels of SOD and GR enzymes caused by indomethacin administration; and 4) all doses of montelukast, lansoprazole, and ranitidine decreased amplification of MPO activity resulting from induced gastric injuries. These results suggest that the gastroprotective effects of montelukast on indomethacin-induced ulcerations can be attributed to its ameliorating effect on oxidative damage and MPO activity.
...
PMID:Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats. 1789 92